Compare Recursion Pharmaceuticals Inc (RXRX) vs Vanguard Total Stock Market Index Fund ETF (VTI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Vanguard Total Stock Market Index Fund ETF — how do they compare? Recursion Pharmaceuticals Inc trades at $3.99 (market cap $2.14B), while Vanguard Total Stock Market Index Fund ETF trades at $381.5 (market cap $2.30T). The key difference: Vanguard Total Stock Market Index Fund ETF is far larger — about 1074.8× Recursion Pharmaceuticals Inc's market cap, and Vanguard Total Stock Market Index Fund ETF is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Recursion Pharmaceuticals Inc for 22 Days and Vanguard Total Stock Market Index Fund ETF for 131 Days on average.
| RXRX | VTI | |
|---|---|---|
Market Cap | $2.14B | $2.30T |
Volume | 30,789,535 | 2,982,924 |
Sector | Health | — |
52-Week High | $6.79 | $384.30 |
52-Week Low | $2.84 | $311.68 |
Typical Hold Time | 22 Days | 131 Days |
Enterprise Value | $1.66B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $4.27, down 7.78% today, with technical indicators showing a bullish trend despite recent weakness. The company reported Q2 2026 earnings miss after two consecutive beats, with revenue declining to $54 million in 2026 from $74 million in 2025. While maintaining a negative net income margin of -961.97%, RXRX continues to expand its AI-powered drug discovery platform through strategic partnerships with Tempus and Roche.
The stock presents high-risk growth potential with strong analyst support (40% buy rating) but faces significant execution challenges. Investment appeal hinges on successful pipeline development and commercialization of AI drug discovery technology, though persistent losses and declining revenue create substantial downside risk for shareholders.
VTI trades at $381.03, down 0.39% on the day, with bullish technical signals from moving averages. The ETF maintains broad exposure to the entire U.S. equity market with over 3,500 holdings. Recent news highlights strong long-term performance potential, with $500 monthly investments since 2001 growing to approximately $876,000 according to The Motley Fool (2026-10-01).
VTI offers diversified U.S. stock market exposure with low expense ratios, making it suitable for long-term investors. Key risks include concentration in top holdings and market volatility. Analyst sentiment remains positive for buy-and-hold strategies, though current RSI levels suggest potential near-term consolidation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Vanguard Total Stock Market Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the index, which represents approximately 100% of the investable US stock market and includes large-, mid-, small-, and micro-cap stocks. It invests by sampling the index, meaning that it holds a broadly diversified collection of securities that, in the aggregate, approximates the full index in terms of key characteristics.
Read more on VTI →
